| Fortive Corporation | ||||||||
| (Exact Name of Registrant as Specified in Its Charter) | ||||||||
| 001-37654 | 47-5654583 | |||||||
| (Commission File Number) | (IRS Employer Identification No.) | |||||||
| 6920 Seaway Blvd | |||||||||||
| Everett, | WA | 98203 | |||||||||
| (Address of principal executive offices) | (Zip code) | ||||||||||
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | ||||
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | ||||
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | ||||
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | ||||
| Title of each class | Trading symbol | Name of each exchange on which registered | ||||||
| Common stock, par value $0.01 per share | FTV | New York Stock Exchange | ||||||
3.700% Notes due 2029 | FTV29 | New York Stock Exchange | ||||||
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS | |||||||
| (d) | Exhibits: | |||||||
| Exhibit No. | Description | |||||||
| 99.1 | ||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
| FORTIVE CORPORATION | |||||||||||
| Date: | July 29, 2026 | By: | /s/ Daniel B. Kim | ||||||||
| Daniel B. Kim | |||||||||||
| Vice President - Associate General Counsel and Secretary | |||||||||||

Fortive Continuing Operations | Q2-26 | Q2-25 | Variance | ||||||||
Revenue | $1,097M | $1,016M | 7.9% / 6.7% (reported / core) | ||||||||
GAAP net earnings | $157M | $112M | 40.9% | ||||||||
GAAP net earnings margin | 14.3% | 11.0% | 330 bps | ||||||||
Adj. EBITDA | $323M | $288M | 12.0% | ||||||||
Adj. EBITDA margin | 29.5% | 28.4% | 110 bps | ||||||||
GAAP diluted earnings per share | $0.51 | $0.33 | 54.5% | ||||||||
Adj. diluted earnings per share | $0.74 | $0.58 | 28.5% | ||||||||
GAAP operating cash flow | $299M | $205M | 45.7% | ||||||||
Free cash flow | $271M | $180M | 50.3% | ||||||||
| TTM GAAP operating cash flow | $1,158M | $1,029M | 12.5% | ||||||||
| TTM free cash flow | $1,044M | $939M | 11.2% | ||||||||
Percentages presented may not recalculate based on the amounts shown due to rounding. | |||||||||||
Intelligent Operating Solutions | Q2-26 | Q2-25 | Variance | ||||||||
Revenue | $758M | $697M | 8.8% / 7.4% (reported / core) | ||||||||
GAAP operating profit | $204M | $171M | 19.1% | ||||||||
GAAP operating margin | 26.8% | 24.5% | 230 bps | ||||||||
Adj. EBITDA | $264M | $236M | 12.2% | ||||||||
Adj. EBITDA margin | 34.9% | 33.8% | 110 bps | ||||||||
Advanced Healthcare Solutions | Q2-26 | Q2-25 | Variance | ||||||||
Revenue | $339M | $320M | 6.0% / 5.3% (reported / core) | ||||||||
GAAP operating profit | $38M | $36M | 7.0% | ||||||||
GAAP operating margin | 11.3% | 11.2% | 10 bps | ||||||||
Adj. EBITDA | $88M | $86M | 2.7% | ||||||||
Adj. EBITDA margin | 26.1% | 26.9% | (80) bps | ||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||||||||||
| July 3, 2026 | June 27, 2025 | July 3, 2026 | June 27, 2025 | ||||||||||||||||||||
| Sales | 1,096.8 | 1,016.4 | 2,166.2 | 2,009.5 | |||||||||||||||||||
| Cost of sales | (401.5) | (370.9) | (795.4) | (726.5) | |||||||||||||||||||
| Gross profit | 695.3 | 645.5 | 1,370.8 | 1,283.0 | |||||||||||||||||||
| Operating costs: | |||||||||||||||||||||||
| Selling, general and administrative | (417.9) | (408.5) | (835.2) | (816.7) | |||||||||||||||||||
| Research and development | (67.5) | (67.2) | (134.0) | (131.2) | |||||||||||||||||||
| Operating profit | 209.9 | 169.8 | 401.6 | 335.1 | |||||||||||||||||||
| Non-operating income (expense), net: | |||||||||||||||||||||||
| Interest expense, net | (35.4) | (32.1) | (67.0) | (64.1) | |||||||||||||||||||
Other non-operating income, net | 5.0 | 1.9 | 8.5 | 2.3 | |||||||||||||||||||
| Earnings from continuing operations before income taxes | 179.5 | 139.6 | 343.1 | 273.3 | |||||||||||||||||||
| Income taxes | (22.2) | (28.0) | (49.4) | (49.1) | |||||||||||||||||||
| Net earnings from continuing operations | 157.3 | 111.6 | 293.7 | 224.2 | |||||||||||||||||||
Net earnings from discontinued operations | — | 55.0 | — | 114.3 | |||||||||||||||||||
| Net earnings | $ | 157.3 | $ | 166.6 | $ | 293.7 | $ | 338.5 | |||||||||||||||
| Net earnings per common share from continuing operations: | |||||||||||||||||||||||
| Basic | $ | 0.52 | $ | 0.33 | $ | 0.96 | $ | 0.66 | |||||||||||||||
| Diluted | $ | 0.51 | $ | 0.33 | $ | 0.95 | $ | 0.65 | |||||||||||||||
| Net earnings per common share from discontinued operations: | |||||||||||||||||||||||
| Basic | $ | — | $ | 0.16 | $ | — | $ | 0.34 | |||||||||||||||
| Diluted | $ | — | $ | 0.16 | $ | — | $ | 0.34 | |||||||||||||||
| Net earnings per share: | |||||||||||||||||||||||
| Basic | $ | 0.52 | $ | 0.49 | $ | 0.96 | $ | 0.99 | |||||||||||||||
| Diluted | $ | 0.51 | $ | 0.49 | $ | 0.95 | $ | 0.99 | |||||||||||||||
| Average common stock and common equivalent shares outstanding: | |||||||||||||||||||||||
| Basic | 304.2 | 339.6 | 306.9 | 340.3 | |||||||||||||||||||
| Diluted | 307.6 | 341.7 | 310.2 | 343.2 | |||||||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||||||||||
| July 3, 2026 | June 27, 2025 | July 3, 2026 | June 27, 2025 | ||||||||||||||||||||
| Sales: | |||||||||||||||||||||||
| Intelligent Operating Solutions | $ | 758.2 | $ | 696.9 | $ | 1,501.4 | $ | 1,387.8 | |||||||||||||||
| Advanced Healthcare Solutions | 338.6 | 319.5 | 664.8 | 621.7 | |||||||||||||||||||
| Total | $ | 1,096.8 | $ | 1,016.4 | $ | 2,166.2 | $ | 2,009.5 | |||||||||||||||
| Operating Profit: | |||||||||||||||||||||||
| Intelligent Operating Solutions | $ | 203.5 | $ | 170.8 | $ | 389.7 | $ | 345.4 | |||||||||||||||
| Advanced Healthcare Solutions | 38.3 | 35.8 | 71.0 | 57.5 | |||||||||||||||||||
Other (a) | (31.9) | (36.8) | (59.1) | (67.8) | |||||||||||||||||||
| Total | $ | 209.9 | $ | 169.8 | $ | 401.6 | $ | 335.1 | |||||||||||||||
| Operating Margins: | |||||||||||||||||||||||
| Intelligent Operating Solutions | 26.8 | % | 24.5 | % | 26.0 | % | 24.9 | % | |||||||||||||||
| Advanced Healthcare Solutions | 11.3 | % | 11.2 | % | 10.7 | % | 9.2 | % | |||||||||||||||
| Total | 19.1 | % | 16.7 | % | 18.5 | % | 16.7 | % | |||||||||||||||
| (a) Operating profit amounts in the “Other” category consist of unallocated corporate costs and other costs not considered part of our evaluation of reportable segment operating performance. | |||||||||||||||||||||||
As of | |||||||||||
| July 3, 2026 | December 31, 2025 | ||||||||||
| ASSETS | (unaudited) | ||||||||||
| Current assets: | |||||||||||
| Cash and equivalents | $ | 374.2 | $ | 375.5 | |||||||
Accounts receivable less allowance for doubtful accounts of $18.8 and $18.8, respectively | 657.8 | 683.6 | |||||||||
| Inventories: | |||||||||||
| Finished goods | 180.0 | 169.9 | |||||||||
| Work in process | 13.3 | 12.3 | |||||||||
| Raw materials | 117.5 | 109.6 | |||||||||
| Inventories | 310.8 | 291.8 | |||||||||
| Prepaid expenses and other current assets | 249.4 | 234.0 | |||||||||
| Current assets, discontinued operations | 4.9 | 20.8 | |||||||||
| Total current assets | 1,597.1 | 1,605.7 | |||||||||
Property, plant and equipment, net of accumulated depreciation of $454.7 and $430.2, respectively | 280.3 | 269.8 | |||||||||
| Other assets | 375.8 | 375.5 | |||||||||
| Goodwill | 7,339.7 | 7,298.3 | |||||||||
| Other intangible assets, net | 2,022.1 | 2,188.4 | |||||||||
| Total assets | $ | 11,615.0 | $ | 11,737.7 | |||||||
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Current portion of long-term debt | $ | — | $ | 899.5 | |||||||
| Trade accounts payable | 427.9 | 436.4 | |||||||||
| Accrued expenses and other current liabilities | 858.7 | 910.7 | |||||||||
| Total current liabilities | 1,286.6 | 2,246.6 | |||||||||
| Other long-term liabilities | 749.7 | 723.5 | |||||||||
| Long-term debt | 3,509.3 | 2,306.5 | |||||||||
| Equity: | |||||||||||
Common stock: $0.01 par value, 2,000 shares authorized; 371.7 and 366.6 issued; 302.6 and 313.4 outstanding; respectively | 3.7 | 3.7 | |||||||||
| Additional paid-in capital | 4,262.7 | 4,210.0 | |||||||||
| Treasury shares, at cost | (3,936.3) | (3,229.8) | |||||||||
| Retained earnings | 5,685.7 | 5,428.5 | |||||||||
| Accumulated other comprehensive income (loss) | 44.8 | 41.0 | |||||||||
| Total Fortive stockholders’ equity | 6,060.6 | 6,453.4 | |||||||||
| Noncontrolling interests | 8.8 | 7.7 | |||||||||
| Total stockholders’ equity | 6,069.4 | 6,461.1 | |||||||||
| Total liabilities and equity | $ | 11,615.0 | $ | 11,737.7 | |||||||
| Six Months Ended | |||||||||||
| July 3, 2026 | June 27, 2025 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Net earnings | $ | 293.7 | $ | 338.5 | |||||||
| Less: net earnings from discontinued operations | — | (114.3) | |||||||||
| Net earnings from continuing operations | 293.7 | 224.2 | |||||||||
| Adjustments to reconcile net earnings to net cash provided by operating activities: | |||||||||||
| Amortization | 184.7 | 182.8 | |||||||||
| Depreciation | 42.4 | 34.4 | |||||||||
| Stock-based compensation | 45.2 | 46.0 | |||||||||
| Change in certain assets and liabilities: | |||||||||||
| Change in accounts receivable, net | 26.0 | 65.2 | |||||||||
| Change in inventories | (20.0) | (39.7) | |||||||||
| Change in trade accounts payable | (7.4) | 17.0 | |||||||||
| Change in prepaid expenses and other assets | (2.5) | (23.3) | |||||||||
| Change in accrued expenses and other liabilities | (43.0) | (109.8) | |||||||||
| Total operating cash provided by continuing operations | 519.1 | 396.8 | |||||||||
| Total operating cash provided by discontinued operations | 1.9 | 156.1 | |||||||||
| Net cash provided by operating activities | 521.0 | 552.9 | |||||||||
| Cash flows from investing activities: | |||||||||||
| Purchases of property, plant and equipment | (54.7) | (46.1) | |||||||||
| Cash paid for acquisitions, net of cash received | (58.1) | — | |||||||||
| All other investing activities | 4.7 | 11.0 | |||||||||
| Total investing cash used in continuing operations | (108.1) | (35.1) | |||||||||
| Total investing cash used in discontinued operations | — | (15.7) | |||||||||
| Net cash used in investing activities | (108.1) | (50.8) | |||||||||
| Cash flows from financing activities: | |||||||||||
Net proceeds from commercial paper borrowings | 433.6 | (253.2) | |||||||||
| Repurchase of common shares | (700.3) | (337.6) | |||||||||
| Payment of dividends | (18.4) | (54.2) | |||||||||
| Proceeds from borrowings (maturities greater than 90 days), net of issuance costs | 1,088.5 | — | |||||||||
| Repayment of borrowings (maturities greater than 90 days) | (1,192.9) | — | |||||||||
| Proceeds from Ralliant Dividend | — | 1,150.0 | |||||||||
| All other financing activities | (10.7) | 7.5 | |||||||||
| Total financing cash (used in) provided by continuing operations | (400.2) | 512.5 | |||||||||
| Total financing cash used in discontinued operations | — | (3.2) | |||||||||
| Net cash (used in) provided by financing activities | (400.2) | 509.3 | |||||||||
| Effect of exchange rate changes on cash and equivalents | 4.1 | 8.0 | |||||||||
| Net change in cash and equivalents | 16.8 | 1,019.4 | |||||||||
| Beginning balance of cash and equivalents | 375.5 | 813.3 | |||||||||
Ending balance of cash and equivalents(a) | $ | 392.3 | $ | 1,832.7 | |||||||
(a) Balance as of July 3, 2026 includes $18.1 million of restricted cash recorded within Prepaid expenses and other current assets in the Consolidated Condensed Balance Sheets, which relates to cash held in escrow for dividend payments which were made to shareholders on July 6, 2026. | |||||||||||
| Three Months Ended July 3, 2026 | |||||||||||||||||
| Intelligent Operating Solutions | Advanced Healthcare Solutions | Total Fortive | |||||||||||||||
| Total Revenue Growth (GAAP) | 8.8 | % | 6.0 | % | 7.9 | % | |||||||||||
| Excluding impact of: | |||||||||||||||||
| Acquisitions and divestitures | (0.4) | % | (0.1) | % | (0.3) | % | |||||||||||
| Currency exchange rates | (1.0) | % | (0.6) | % | (0.9) | % | |||||||||||
| Core Revenue Growth (Non-GAAP) | 7.4 | % | 5.3 | % | 6.7 | % | |||||||||||
| Three Months Ended | |||||||||||
| $ in millions | July 3, 2026 | June 27, 2025 | |||||||||
| Revenue (GAAP) | $ | 1,096.8 | $ | 1,016.4 | |||||||
| Net Earnings from Continuing Operations (GAAP) | $ | 157.3 | $ | 111.6 | |||||||
| Interest expense, net | 35.4 | 32.1 | |||||||||
| Income taxes | 22.2 | 28.0 | |||||||||
| Depreciation | 22.0 | 17.6 | |||||||||
| Amortization | 91.5 | 91.6 | |||||||||
| EBITDA (Non-GAAP) | 328.4 | 280.9 | |||||||||
Pretax acquisition, divestiture, and Separation related items (a) | 1.4 | 1.6 | |||||||||
| Pretax discrete restructuring charges | 2.4 | 8.0 | |||||||||
| Pretax foreign currency transaction (gains) and losses related to Euro-denominated debt | (4.6) | — | |||||||||
| Pretax IEEPA tariff refunds | (4.5) | — | |||||||||
| Pretax gain from divestiture | — | (2.1) | |||||||||
| Adjusted EBITDA (Non-GAAP) | $ | 323.1 | $ | 288.4 | |||||||
| Net Earnings Margin from Continuing Operations (GAAP) | 14.3 | % | 11.0 | % | |||||||
Adjusted EBITDA Margin (Non-GAAP) | 29.5 | % | 28.4 | % | |||||||
(a) Includes pretax transaction costs, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs recorded in Net earnings from continuing operations. | |||||||||||
| Three Months Ended July 3, 2026 | Three Months Ended June 27, 2025 | ||||||||||||||||||||||
| $ in millions | Intelligent Operating Solutions | Advanced Healthcare Solutions | Intelligent Operating Solutions | Advanced Healthcare Solutions | |||||||||||||||||||
| Revenue (GAAP) | $ | 758.2 | $ | 338.6 | $ | 696.9 | $ | 319.5 | |||||||||||||||
| Operating Profit (GAAP) | $ | 203.5 | $ | 38.3 | $ | 170.8 | $ | 35.8 | |||||||||||||||
| Amortization of acquisition-related intangible assets | 47.7 | 43.8 | 46.6 | 45.0 | |||||||||||||||||||
Acquisition, divestiture, and Separation related items (a) | 0.4 | 0.6 | 0.4 | — | |||||||||||||||||||
| Discrete restructuring charges | 0.1 | 1.2 | 5.9 | — | |||||||||||||||||||
| IEEPA tariff refunds | (3.7) | (0.8) | — | — | |||||||||||||||||||
| Adjusted Operating Profit (Non-GAAP) | 248.0 | 83.1 | 223.7 | 80.8 | |||||||||||||||||||
| Depreciation | 16.4 | 5.3 | 12.0 | 5.3 | |||||||||||||||||||
| Adjusted EBITDA (Non-GAAP) | $ | 264.4 | $ | 88.4 | $ | 235.7 | $ | 86.1 | |||||||||||||||
| Operating Profit Margin (GAAP) | 26.8 | % | 11.3 | % | 24.5 | % | 11.2 | % | |||||||||||||||
| Adjusted Operating Profit Margin (Non-GAAP) | 32.7 | % | 24.5 | % | 32.1 | % | 25.3 | % | |||||||||||||||
| Adjusted EBITDA Margin (Non-GAAP) | 34.9 | % | 26.1 | % | 33.8 | % | 26.9 | % | |||||||||||||||
| (a) Includes pretax transaction costs, integration costs, corresponding restructuring charges related to acquisitions, and certain Separation-related costs. | |||||||||||||||||||||||
| Three Months Ended | Trailing Twelve Months | ||||||||||||||||||||||||||||
| ($ in millions) | July 3, 2026 | April 3, 2026 | December 31, 2025 | September 26, 2025 | |||||||||||||||||||||||||
Operating Cash Flows from Continuing Operations (GAAP) | $ | 298.7 | $ | 220.4 | $ | 344.2 | $ | 294.7 | $ | 1,158.0 | |||||||||||||||||||
| Less: Purchases of property, plant & equipment (capital expenditures) (GAAP) | (28.1) | (26.6) | (30.4) | (28.6) | (113.7) | ||||||||||||||||||||||||
| Free Cash Flow (Non-GAAP) | $ | 270.6 | $ | 193.8 | $ | 313.8 | $ | 266.1 | $ | 1,044.3 | |||||||||||||||||||
| Three Months Ended | Trailing Twelve Months | ||||||||||||||||||||||||||||
| ($ in millions) | June 27, 2025 | March 28, 2025 | December 31, 2024 | September 27, 2024 | |||||||||||||||||||||||||
Operating Cash Flows from Continuing Operations (GAAP) | $ | 205.0 | $ | 191.8 | $ | 327.7 | $ | 304.7 | $ | 1,029.2 | |||||||||||||||||||
| Less: Purchases of property, plant & equipment (capital expenditures) (GAAP) | (25.0) | (21.1) | (22.6) | (21.6) | (90.3) | ||||||||||||||||||||||||
| Free Cash Flow (Non-GAAP) | $ | 180.0 | $ | 170.7 | $ | 305.1 | $ | 283.1 | $ | 938.9 | |||||||||||||||||||